PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1507326
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1507326
Global Attention Deficit Hyperactivity Disorder Market is valued approximately USD 14.3 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.70% over the forecast period 2024-2032. Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder that typically manifests in childhood and often continues into adulthood. It is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. Also, new and improved medications are continually being developed. There is a shift towards long-acting stimulants and non-stimulant medications, offering more options for patients who may not respond well to traditional treatments. Non-stimulant medications, such as guanfacine and atomoxetine, are gaining popularity due to their lower risk of abuse and better side effect profiles for some patients. Thus, this trend is anticipated to support the growth of Global Attention Deficit Hyperactivity Disorder Market
Moreover, the awareness and recognition of ADHD have increased globally, leading to higher diagnosis rates. Improved diagnostic criteria and better screening processes have contributed to more individuals being identified and treated for ADHD. Also, there have been significant advancements in both pharmacological and non-pharmacological treatments for ADHD. New medications with improved efficacy and safety profiles, as well as behavioral therapies and digital therapeutics, are expanding the market. Additionally, growing public and professional awareness about ADHD, its symptoms, and its impact on quality of life is encouraging more people to seek diagnosis and treatment. Educational campaigns and advocacy by healthcare organizations and patient groups are instrumental in this regard, which anticipated to support the market growth. However, the stringent administration and governing procedures, an upsurge in medication prices, and the limited availability of non-stimulants ADHD drugs are the factors most expected to hinder the growth of the Global Attention Deficit Hyperactivity Disorder Market during the forecast period 2024-2032.
The key regions considered for the Global Attention Deficit Hyperactivity Disorder Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue. The attention deficit hyperactivity disorder market in North America is expanding owing to the introduction and rapid adoption of various medications. Furthermore, favourable reimbursement policies, increasing awareness of current treatment methods, improved patient affordability, and the introduction of new products are all expected to propel market expansion throughout the projection period. In September 2023, Tris Pharma, Inc. announced that Health Canada had approved the use of Quillivant ER (extended-release) to treat ADHD in children aged six to twelve years. Quillivant ER will be available in oral suspension and chewable tablet forms, marking the first time in Canada that once-daily, long-acting methylphenidate chewable and oral suspension formulations have been approved for ADHD treatment. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period.